HRT Telehealth Pricing and Program Fees

Direct answer

Telehealth hormone-replacement therapy pricing now includes membership, pay-per-visit, insurance-billable, bundled, and formulation-specific models. RightFit tracks HRT-related care from Evernow, Midi Health, Mochi, Henry, Effecty, NavioMD, Musely, Winona, and Alloy. Medication price, visit fee, membership, formulation, preparation type, commitment, and included services are stored separately so unlike commercial models do not appear equivalent.

Estradiol

Progesterone

Mochi uses medication pricing plus membership

Mochi’s current HRT materials publish starting medication prices for estradiol tablet, estradiol patch, and progesterone while requiring a separate Mochi membership. RightFit keeps the medication observations and membership fee separate so the lowest medication amount is not presented as the complete recurring care cost.

Henry uses a bundled HRT program model

Henry’s current HRT materials publish a monthly program amount across eligible estrogen and progesterone options and state that testosterone, if prescribed, carries an additional charge. The current RightFit records also identify clinician access and shipping as included in the HRT program structure.

That model differs from a medication-plus-membership structure. RightFit does not divide Henry’s bundled amount into invented medication-specific prices, and it does not add Mochi’s medication prices into a fictional bundled program that the provider did not publish.

Effecty uses formulation-specific pricing and longer-term discounts

Effecty’s current treatment catalog publishes distinct prices for estradiol tablet, patch, and cream, with lower effective monthly rates tied to a twelve-month supply purchase. RightFit preserves the ordinary price and the term-dependent rate separately because the lower amount carries a different commitment.

NavioMD provides another progesterone program model

NavioMD’s current structured progesterone record uses a compounded oral capsule with a published monthly medication amount and program terms selected at checkout. The record also identifies included membership, clinician access, and shipping. This adds another example of why a progesterone price needs its provider-specific services and preparation type beside it.

FDA distinguishes approved hormone therapies from compounded products

FDA’s current menopause guidance states that FDA-approved hormone therapies are available for menopausal symptoms and separately notes that many products marketed as compounded bioidentical hormones are not FDA-approved. RightFit therefore keeps preparation type and source context visible and does not treat the word bioidentical as a regulatory category or proof of superior safety.

Current FDA labeling context changed in 2026

FDA approved prescribing-information changes for multiple menopausal hormone-therapy products in 2026. Those updates reinforce the need to use current product-specific regulator sources rather than repeating older blanket summaries. RightFit does not assume that one label change applies identically to every estrogen or progesterone product.

Formulation is part of the commercial comparison

Estradiol tablet, patch, and cream can carry different provider prices even within the same company. Progesterone can also appear as an oral product or compounded topical formulation. RightFit keeps those formulation records separate so one lower-priced route does not become the market price for the entire HRT category.

Another hormone can create an additional program cost

A provider can publish one base HRT program while charging separately when another hormone is prescribed. Henry currently identifies an additional charge for testosterone when it is part of the clinician-selected plan. RightFit keeps that conditional additional cost outside the base estradiol or progesterone record until the source establishes that it applies.

Included services can differ even when medication prices look similar

One provider may include clinician access and shipping in a bundled HRT amount, while another may publish a lower medication price alongside a recurring membership. A fair commercial comparison therefore identifies which services are inside the displayed amount before interpreting the difference.

Laboratory costs remain separate when not clearly published

Hormone-care programs can involve laboratory testing, but not every provider publishes one universal lab fee or inclusion for every HRT patient. RightFit records labs only when the provider source makes the commercial term clear. An unlisted lab charge is not treated as free and is not added speculatively.

State availability should stay program-specific

A provider’s general telehealth footprint does not prove that every HRT formulation is available in every state. Clinician licensure, pharmacy availability, formulation, and provider policy can differ. RightFit only publishes program-level state coverage when a current source supports it.

What to compare across HRT telehealth programs

• Exact hormone and formulation.
• Route and preparation type.
• Normal medication or program price.
• Promotional or longer-term effective price.
• Required membership or recurring care fee.
• Commitment and amount billed for the term.
• Whether clinician access and shipping are included.
• Whether labs are included, separate, or unverified.
• Any additional price for another prescribed hormone.
• Program-level state availability when verified.
• Provider-primary source and last-verification date.

What RightFit will not infer

• The lowest medication price does not establish the lowest complete care cost.
• A bundled HRT price is not divided into invented medication-only prices.
• Tablet, patch, cream, and capsule formulations are not treated as interchangeable.
• A compounded bioidentical product is not described as FDA-approved because an ingredient has an approved product.
• A twelve-month effective rate is not treated as true month-to-month billing.
• A missing lab price is not treated as zero.
• The pricing page does not determine which hormone or formulation is appropriate for an individual.

Why HRT price history needs component-level tracking

A provider can change one HRT component without changing the others: medication price, membership, testosterone add-on, included services, or plan term. RightFit should record the specific commercial change rather than treating every update as a new overall HRT price. That makes future comparison reports more useful and auditable.

Questions a reader can use

• What exact hormone and formulation is included?
• Is the amount medication-only or a bundled care program?
• Is a membership charged separately?
• Does a lower rate require a long-term supply purchase?
• Are clinician visits and shipping included?
• Are labs included or billed separately?
• Could another prescribed hormone add to the recurring cost?
• Is the exact formulation available in my state?
• Is the product FDA-approved or compounded?
• When were the provider and regulator sources last checked?

What this comparison cannot decide

A public HRT pricing comparison cannot determine whether hormone therapy is appropriate for an individual, which hormone or formulation should be used, or what monitoring is appropriate. Those are individualized clinical decisions. RightFit’s role is to make the commercial structure and source evidence understandable without converting price into treatment advice.

Bottom line

Telehealth HRT pricing spans insurance-billable visits, pay-per-visit care, memberships, bundled programs, formulation-specific medication prices, and compounded formulas. Evernow and Midi add two different clinician-access models alongside Mochi, Henry, Effecty, NavioMD, Musely, Winona, and Alloy. RightFit keeps clinical fees and medication pricing separate instead of forcing every provider into one HRT cost format.

Why a provider-level HRT average can hide the real program structure

A provider can list several hormone formulations under one recurring care amount, while another publishes a separate price for every medication and adds a membership. Averaging those provider numbers without identifying the pricing model would mix bundled care with medication-only components. RightFit therefore keeps provider-level summaries secondary to the underlying hormone, formulation, and fee records.

Why preparation type can matter even when the ingredient name is familiar

The current HRT dataset contains both products whose preparation type is not characterized as compounded in the public record and products that are explicitly compounded, such as Henry’s progesterone cream and NavioMD’s progesterone capsules. RightFit does not infer preparation type from marketing language. It records compounded status only when the source or product record supports it and keeps FDA-approved-product context separate.

A complete HRT comparison should preserve both care and product layers

The product layer identifies hormone, route, formulation, preparation type, and medication price. The care layer identifies membership, clinician access, labs, shipping, commitment, and conditional add-ons. Keeping both layers makes it possible to compare a bundled program with a medication-plus-membership program without erasing how either provider actually charges.

The same component-level method also prevents one conditional add-on from distorting the whole HRT market. A testosterone add-on, special formulation, or longer-term discount should change only the applicable program record. The base HRT price, estradiol or progesterone record, membership, and other verified fees remain independently traceable so later reports can explain exactly what changed and why.

For launch QA, every displayed HRT amount should therefore retain its formulation, fee model, and verification date so future refreshes can distinguish a medication change from a program-fee change.

Musely adds another compounded HRT model

Musely’s current menopause catalog includes a compounded oral estradiol pill at $35 per month, a compounded topical Estrogen Cream at $46 per month using estriol and estradiol with progesterone when applicable, and a compounded micronized progesterone pill at $20 per month. Musely also charges a $20 first-order or new-treatment doctor visit that can cover multiple treatments ordered during the same initial visit.